Arca
Skip to content
Tools
Tools

Post-polycythemia vera myelofibrosis

Drug research and approvals for post-polycythemia vera myelofibrosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 20 studies of post-polycythemia vera myelofibrosis are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.

  • Recruiting worldwide: 20
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 20 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
Nov 29, 2019A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…Pacritinib (SB1518) / Ruxolitinib / Hydroxyurea / DanazolSobiOngoing
Nov 13, 2019A randomized, double-blind, phase 3 study to evaluate the activity of momelotinib (MMB) versus danazol (DAN) in symptomatic, anemic subjects with primary…Momelotinib (MMB) / DanazolSierra OncologyOngoing
Feb 28, 2018Extended access of momelotinib for subjects with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis…MomelotinibGSKClosed
Jan 10, 2017A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients.Jakavi (INC424, ruxolitinib)Novartis PharmaceuticalsClosed
May 9, 2014A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…Pacritinib (SB1518)Cti BiopharmaOngoing

FDA orphan designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Nov 16, 2011JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis…Incyte CorporationApproved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.